CDC warns of rising spread of babesiosis through blood transfusions http://t.co/lTwKaKL
265 days ago
Very disappointing study, scary how decisions based on so few #s: Cancer trial participation less than 1% http://t.co/RhY7Mkg via @addthis
276 days ago
You may have already seen blog @ Digital Pathology Blog but check out the Pathology Visions Conference-should be great! http://t.co/TVW0M7P
279 days ago
WCLC 2011 Oral Presentations: (More) Genomics http://t.co/xIOaw9j
279 days ago
I have seen a few requests for send-out genotype testing for CYPD6, the cytochrome P450 enzyme in localized to the liver that converts tamoxifen to its active metabolite, endoxifen. In my post-ASCO meeting mop-up, one of the ResearchtoPractice5-Minute Journal Club's called to my attention two abstracts from that meeting studying the impact of CYPD6 inhibitors on breast cancer recurrence in patients receiving tamoxifen.
Both of these studies have significant methodological problems that limit the significance of their conclusions but they nevertheless are important to be aware of because they point out the potential pharmacological interaction between SSRIs and tamoxifen and the possible effects of that interaction on breast cancer recurrence and adherence to tamoxifen therapy. Additional studies need to be done that look at the genetic variants of CYPD6 and the interaction with inhibitors with regard to TAM therapy.
At this point, I don't see that CYPD6 testing is going to become routine, but this might be a good conversation with your friendly neighborhood oncologist or pathologist.
I have seen a few requests for send-out genotype testing for CYPD6, the cytochrome P450 enzyme in localized to the liver that converts tamoxifen to its active metabolite, endoxifen. In my post-ASCO meeting mop-up, one of the ResearchtoPractice 5-Minute Journal Club's called to my attention two abstracts from that meeting studying the impact of CYPD6 inhibitors on breast cancer recurrence in patients receiving tamoxifen.
Both of these studies have significant methodological problems that limit the significance of their conclusions but they nevertheless are important to be aware of because they point out the potential pharmacological interaction between SSRIs and tamoxifen and the possible effects of that interaction on breast cancer recurrence and adherence to tamoxifen therapy. Additional studies need to be done that look at the genetic variants of CYPD6 and the interaction with inhibitors with regard to TAM therapy.
At this point, I don't see that CYPD6 testing is going to become routine, but this might be a good conversation with your friendly neighborhood oncologist or pathologist.
Below are links to these abstracts:
Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors.
Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study.